Literature DB >> 17084334

Insular thyroid carcinoma: collective analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation therapy.

Hung-Wen Lai1, Chen-Hsen Lee, Jui-Yu Chen, Ling-Ming Tseng, An-Hang Yang.   

Abstract

BACKGROUND: Insular thyroid carcinoma is a distinctive clinicopathologic entity with aggressive behavior and frequent lethal disease. But because it is rare, no single institute has sufficient experience with the clinicopathologic features and treatment effect of radioiodine. A literature review and collective analysis might facilitate patient management.
METHODS: From January 1991 to December 2005, 9 patients with insular thyroid carcinoma were diagnosed in Taipei Veterans General Hospital. Clinicopathologic data were collected for analysis. The English literature about insular carcinoma was searched in Medline. Patients with detailed descriptions of treatment and followup were enrolled. Clinicopathologic features, rate of lymph node and distant metastasis, and prognostic factors were analyzed.
RESULTS: Seventy-three of 486 patients collected from 23 articles with detailed description of treatment and followup were combined with our 9 patients for analysis, making a total of 82 patients in this article. The mean period of patient followup was 84.5 months. There were 26 (31.7%) men and 56 (68.3%) women. The rate of lymph node metastasis was 49%, and distant metastasis was 57.5%. Disease-specific death rate was 37.8%. The 5- and 10-year survival rates of insular carcinoma were 72.2% and 52%, respectively. Patient age older than 45 years (p=0.0004) and distant metastasis (p<0.0001) were poor prognostic factors. Use of radioiodine therapy (p=0.9789) and radiation therapy (p=0.2172) were not associated with prolonged survival.
CONCLUSIONS: Patients with insular thyroid carcinoma have unfavorable outcomes. Postoperative radioiodine therapy or radiotherapy seemed not to be strongly associated with prolonged survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17084334     DOI: 10.1016/j.jamcollsurg.2006.07.008

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  10 in total

Review 1.  An evidence-based review of poorly differentiated thyroid cancer.

Authors:  Enoch M Sanders; Virginia A LiVolsi; James Brierley; Jennifer Shin; Gregory W Randolph
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 2.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

3.  Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours.

Authors:  Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

4.  Multifocality predicts poor outcome of patients with insular thyroid cancer: a clinicopathological study.

Authors:  Lei Liu; Dapeng Li; Hailing Wang; Xiaoyong Yang; Yang Yu; Ming Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.

Authors:  Matthew W Rosenbaum; Benjamin J Gigliotti; Sara I Pai; Sareh Parangi; Heather Wachtel; Mari Mino-Kenudson; Viswanath Gunda; William C Faquin
Journal:  Endocr Pathol       Date:  2018-03       Impact factor: 3.943

6.  Neoadjuvant chemotherapy in 13 patients with locally advanced poorly differentiated thyroid carcinoma based on Turin proposal - a single institution experience.

Authors:  Nikola Besic; Marta Dremelj; Andreja Schwartzbartl-Pevec; Barbara Gazic
Journal:  Radiol Oncol       Date:  2015-08-21       Impact factor: 2.991

7.  Application of intensity-modulated radiotherapy in unresectable poorly differentiated thyroid carcinoma.

Authors:  Fen Xue; Duanshu Li; Chaosu Hu; Zhuoying Wang; Xiayun He; Yi Wu
Journal:  Oncotarget       Date:  2017-02-28

8.  Postoperative radioiodine therapy impact on survival in poorly differentiated thyroid carcinoma: a population-based study.

Authors:  Lei Xu; Qiong Zou; Ju Jiao; Yong Zhang
Journal:  Nucl Med Commun       Date:  2022-02-01       Impact factor: 1.690

Review 9.  Poorly differentiated thyroid carcinoma: a clinician's perspective.

Authors:  Junyu Tong; Maomei Ruan; Yuchen Jin; Hao Fu; Lin Cheng; Qiong Luo; Zhiyan Liu; Zhongwei Lv; Libo Chen
Journal:  Eur Thyroid J       Date:  2022-03-24

Review 10.  Strategies for Radioiodine Treatment: What's New.

Authors:  Clotilde Sparano; Sophie Moog; Julien Hadoux; Corinne Dupuy; Abir Al Ghuzlan; Ingrid Breuskin; Joanne Guerlain; Dana Hartl; Eric Baudin; Livia Lamartina
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.